Aktis Oncology, Inc.
AKTS
$20.34
$1.226.38%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | 72.57% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 72.57% | ||||
| Cost of Revenue | 21.48% | ||||
| Gross Profit | -14.95% | ||||
| SG&A Expenses | 114.28% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 34.75% | ||||
| Operating Income | -30.68% | ||||
| Income Before Tax | -21.05% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -21.05% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -21.05% | ||||
| EBIT | -30.68% | ||||
| EBITDA | -32.22% | ||||
| EPS Basic | 97.93% | ||||
| Normalized Basic EPS | 97.93% | ||||
| EPS Diluted | 97.93% | ||||
| Normalized Diluted EPS | 97.93% | ||||
| Average Basic Shares Outstanding | 5,750.58% | ||||
| Average Diluted Shares Outstanding | 5,750.58% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||